Makena
Brand for: Hydroxyprogesterone
My Prescription
Payment
Select pharmacy
$161.57
$15.00 due at pharmacy
$161.57 - $15.00 = $146.57
$146.57 remaining balance
You will be given your coupon after you complete your purchase with PayPal.
AlbertsonsPowered by$161.57
Print or send this coupon to your phone
AlbertsonsPowered byAbout Makena
Drug Details
Hydroxyprogesterone is an injectable medication primarily used to manage menstrual irregularities caused by hormonal imbalances and to treat advanced uterine cancer. Administered as an injection into the buttock muscle, it may cause temporary pain or swelling at the site. This medication functions as a progestin, mimicking the natural hormone progesterone to help regulate the uterine lining and maintain normal menstrual cycles. In cases of uterine cancer, hydroxyprogesterone aids in inhibiting the growth of cancerous cells in the uterine lining. It is important to consult with healthcare professionals before using this medication to ensure it is appropriate for your specific condition.
Makena (Hydroxyprogesterone) dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 1ML of 250MG/ML | 1 Vial | $161.57 | $161.57 |
| 1ML of 250MG/ML | 2 Vials | $315.15 | $157.58 |
| 1ML of 250MG/ML | 3 Vials | $468.72 | $156.24 |
Makena FAQs
Makena is used to help reduce the risk of preterm birth in women who are pregnant with a single baby and have a history of spontaneous preterm birth. It is a form of progesterone, a hormone that plays a key role in maintaining pregnancy.
Makena was taken off the market because the U.S. Food and Drug Administration (FDA) determined that the drug was not effective in reducing the risk of preterm birth. Despite initial approval based on early studies, subsequent research did not confirm its efficacy. As a result, the FDA recommended its withdrawal to ensure that patients receive treatments that are both safe and effective.
Yes, Makena is no longer FDA approved. The U.S. Food and Drug Administration (FDA) withdrew its approval for Makena, a drug intended to reduce the risk of preterm birth, due to concerns about its effectiveness.
The Makena shot is used to help reduce the risk of preterm birth in women who are pregnant with a single baby and have a history of spontaneous preterm birth.
As of October 2023, Makena, a drug used to reduce the risk of preterm birth, is no longer available in the United States. The FDA withdrew its approval due to concerns about its effectiveness. Patients should consult their healthcare providers for alternative treatments or options.